Published in Hepatitis Weekly, July 7th, 1997
This new assay could advance the monitoring of patients after withdrawal of immunosuppressive therapy, as well as help identify patients with autoimmune hepatitis type 2 (AIH-2) and a dominant presentation in order to begin early immunosuppressive treatment, researcher Ana Maria Yamamoto and colleagues noted.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.